Regístrese
Buscar en
Gastroenterología y Hepatología (English Edition)
Toda la web
Inicio Gastroenterología y Hepatología (English Edition) Anti-tumour necrosis factor agents in Crohn's disease and ulcerative colitis...
Journal Information
Vol. 41. Issue 9.
Pages 576-582 (November 2018)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 41. Issue 9.
Pages 576-582 (November 2018)
Review
DOI: 10.1016/j.gastre.2018.06.014
Anti-tumour necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease
Agentes anti-factor de necrosis tumoral en enfermedad de Crohn y colitis ulcerosa: más allá de la enfermedad luminal
Visits
0
Laura Núñez-Gómez
Corresponding author
laura.ngz@hotmail.com

Corresponding author.
, Francisco Mesonero-Gismero, Agustín Albillos-Martínez, Antonio López-Sanromán
Servicio de Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, Madrid, Spain
This item has received
0
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Predictors of good response to anti-TNF treatment in patients with stenosing Crohn's disease (results of the CREOLE study).
Abstract

Anti-tumour necrosis factor agents (anti-TNF) drugs are commonly used in patients with inflammatory bowel disease (IBD) and have proven effective in both induction and maintenance therapy in luminal Crohn's disease and ulcerative colitis. Their efficacy has also been proven in fistulising perianal Crohn's disease. However, the evidence in other scenarios, such as stricturing, penetrating and non-fistulising perianal Crohn's disease, extraintestinal IBD manifestations and ileoanal reservoir complications, is not as robust. The aim of this review was to perform an analysis of the available literature and to determine the role of anti-TNF drugs in common clinical practice in patients affected by these complications.

Keywords:
Inflammatory bowel disease
Crohn's disease
Ulcerative colitis
Anti-TNF
Resumen

Los agentes anti-factor de necrosis tumoral (anti-TNF) son fármacos de uso común en los pacientes con enfermedad inflamatoria crónica intestinal (EICI) y han demostrado ser efectivos en inducción y mantenimiento en enfermedad de Crohn y colitis ulcerosa, así como en pacientes con afectación fistulizante perianal. Sin embargo, la evidencia relativa al uso de estos fármacos en otros escenarios dentro de EICI es menos sólida. Es el caso de la enfermedad de Crohn con afectación estenosante, penetrante o perianal no fistulizante, de las manifestaciones extraintestinales de la EICI y de las complicaciones del reservorio ileoanal. El objetivo de esta revisión fue realizar un análisis de la literatura disponible y determinar el papel de los anti-TNF en la práctica clínica en pacientes afectos por estas complicaciones.

Palabras clave:
Enfermedad inflamatoria intestinal
Enfermedad de Crohn
Colitis ulcerosa
Anti-TNF

Article

These are the options to access the full texts of the publication Gastroenterología y Hepatología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Gastroenterología y Hepatología (English Edition)

Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.